$5.47
2.53% today
Nasdaq, Feb 28, 04:49 pm CET
ISIN
US83422E1055
Symbol
SLDB
Sector
Industry

Solid Biosciences Inc. Stock price

$5.33
+2.19 69.75% 1M
-3.82 41.75% 6M
+1.33 33.25% YTD
-4.75 47.12% 1Y
-6.89 56.38% 3Y
-39.00 87.98% 5Y
-333.97 98.43% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.04 0.76%
ISIN
US83422E1055
Symbol
SLDB
Sector
Industry

Key metrics

Market capitalization $406.78m
Enterprise Value $260.38m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.24
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-112.10m
Free Cash Flow (TTM) Free Cash Flow $-91.73m
Cash position $171.12m
EPS (TTM) EPS $-3.04
P/E forward negative
Short interest 13.24%
Show more

Is Solid Biosciences Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Solid Biosciences Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Solid Biosciences Inc. forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a Solid Biosciences Inc. forecast:

Buy
100%

Financial data from Solid Biosciences Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 2.55 2.55
12% 12%
-
-2.55 -2.55
12% 12%
-
- Selling and Administrative Expenses 26 26
14% 14%
-
- Research and Development Expense 81 81
2% 2%
-
-110 -110
1% 1%
-
- Depreciation and Amortization 2.55 2.55
12% 12%
-
EBIT (Operating Income) EBIT -112 -112
1% 1%
-
Net Profit -102 -102
13% 13%
-

In millions USD.

Don't miss a Thing! We will send you all news about Solid Biosciences Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Solid Biosciences Inc. Stock News

Positive
MarketBeat
9 days ago
Shares of biotech company Solid Biosciences NASDAQ: SLDB skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%.
Neutral
GlobeNewsWire
10 days ago
CHARLESTOWN, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the pricing of an underwritten offering of 35,739,810 shares of its common stock at an offering price of $4.03 per share and, in lieu of common stock to certa...
Neutral
GlobeNewsWire
10 days ago
— Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% (N=3) and significant improvements in multiple additional muscle health biomarkers observed support the potential of SGT-003 as a next-generation, best-in-class Duchenne muscular dystrophy gene therapy candidate —— Encouraging early signals of potential...
More Solid Biosciences Inc. News

Company Profile

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Alexander Cumbo
Employees 88
Founded 2013
Website www.solidbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today